Jefferies Downgrades Immunogen Inc. (IMGN) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/31/2026
- Nasdaq leads Wall Street gains as Amazon rally offsets Apple decline
- Amazon shares rally as cloud growth surges and spending outlook climbs
- Apple shares sink on disappointing September quarter sales outlook
- Novo Nordisk stock tumbles 10% as key trial misses goal
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- Wall Street ends sharply higher, lifted by soaring Microsoft
- KBR names its Mission Technology Solutions spinoff Trinzic
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- AbbVie (ABBV) Misses Q2 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
- Rivian Automotive (RIVN) Tops Q2 EPS by 20c, Tops on Revenue; Delivers 12,194 EVs
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
Immunogen (IMGN) PT Cut to $9 at Cantor Fitzgerald
December 22, 2014 7:50 AM ESTCantor Fitzgerald analyst Mara Goldstein reiterated a Hold rating and lowered her price target on Immunogen Inc. (NASDAQ: IMGN) price target of $9.00 (from $14.00) on disappointing MARIANNE news.
Goldstein said Friday's 40% sell-off have been an overreaction but they remain on the sidelines. "The... More
Leerink Swann Downgrades Immunogen Inc. (IMGN) to Market Perform
December 19, 2014 1:36 PM ESTLeerink Swann downgraded Immunogen Inc. (NASDAQ: IMGN) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Immunogen Inc. click here. For more ratings news on Immunogen Inc. click here.
Shares of Immunogen Inc. closed at $10.85 yesterday.
... MoreImmunogen (IMGN) PT to $10 at Credit Suisse on Disappointing MARIANNE Trial Results
December 19, 2014 9:32 AM ESTCredit Suisse analyst Jason Kantor cut estimates and his price target on Neutral-rated Immunogen Inc. (NASDAQ: IMGN) to $10.00 (from $14.00) following disappoint MARIANNE data.
Kantor said investors largely assumed the data would be positive and Kadcyla would be a multi-billion dollar drug. The news... More
Immunogen (IMGN) Declines; Roche Reports Disappointing MARIANNE Trial Results
December 19, 2014 8:01 AM ESTImmunoGen, Inc.(NASDAQ: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today reported that Roche (OTC: RHHBY) has announced top-line results of its Phase III MARIANNE study.
The study evaluated three HER2-targeted regimens Kadcyla® (ado-trastuzumab emtansine) plus Perjeta® (pertuzumab), Kadcyla alone, and Herceptin® (trastuzumab) plus taxane chemotherapy in people with previously... More
